LEO Pharma Boosts Revenue 10% on Dermatology Growth, Strengthens Rare Disease Pipeline — LEO Pharma A/S

Event summary

LEO Pharma reported 10% revenue growth at constant exchange rates (CER) in H1 2026, driven by its dermatology portfolio.
The company agreed to acquire global rights for dersimelagon, an investigational first-in-class oral therapy for rare genetic skin diseases, with a potential launch in 2027.
Revenue from strategic brands Anzupgo®, Spevigo®, and Adtralza®/Adbry® increased by 50% (CER) compared to H1 2025.
Adjusted EBITDA margin decreased to 17% from 21% in H1 2025 due to increased investments in commercial and innovation activities.
LEO Pharma updated its 2026 outlook, expecting revenue growth of 9-11% at CER and an adjusted EBITDA margin of 14-16%.

The big picture

LEO Pharma's strong revenue growth in H1 2026 highlights the company's focus on expanding its dermatology portfolio and strengthening its pipeline in rare genetic skin diseases. The acquisition of dersimelagon and the addition of Replay's gene therapy platform position LEO Pharma to address significant unmet medical needs, potentially driving long-term growth. However, the company's ability to balance increased investments with profitability will be a key factor in its success.

What we're watching

Pipeline Expansion: The acquisition of dersimelagon and the addition of Replay's gene therapy platform will strengthen LEO Pharma's pipeline in rare genetic skin diseases, potentially driving future growth.
Financial Performance: The company's ability to sustain revenue growth while managing increased investments in commercial and innovation activities will be crucial for maintaining profitability.
Regulatory Approvals: The pace at which dersimelagon and other pipeline products receive regulatory approvals will impact LEO Pharma's ability to meet its updated financial outlook.